{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-002083","form_type":"8-K","ticker":null,"cik":"0001029125","company_name":"Panbela Therapeutics, Inc.","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.152054+00:00","generated_at":"2026-06-06T17:17:29.355918+00:00","sec_items":["3.01","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Panbela faces Nasdaq delisting over public float shortfall; ASPIRE trial enrollment >50%","bullets":["Nasdaq staff notified Panbela that after 1-for-20 reverse split on Jan 18, publicly held shares fell below 500,000 minimum.","Delisting hearing scheduled for bid price and equity compliance; this additional non-compliance basis will be considered by panel.","Common stock remains listed on Nasdaq Capital Market pending hearing outcome; no assurance of continued listing.","ASPIRE global phase 3 trial for ivospemin in metastatic pancreatic cancer exceeded 50% enrollment; interim data expected mid-2024.","Full enrollment projected by Q1 2025; trial has about 90 sites across US, Europe, Australia, and South Korea."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-002083","json":"https://secwatch.observer/filing/0001437749-24-002083.json","markdown":"https://secwatch.observer/filing/0001437749-24-002083.md","text":"https://secwatch.observer/filing/0001437749-24-002083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/0001437749-24-002083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/pbla20240124_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T17:17:29.355918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ab7c4541a5d6bcff8ea17ee5c02ebdd9e0fc944","claim":"Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(4)).","evidence_excerpt":"January 22, 2024, Panbela Therapeutics, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as of effective date of the previously reported 1-for-20 reverse stock split on January 18, 2024, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”), which requires a minimum of 500,000 publicly held shares. The Staff informed the Company that this matter serves as an additional basis for delisting the Company’s common stock and that the Nasda","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/0001437749-24-002083-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5550(a)(4)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}